Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities

Additional details will be provided during Azenta's fourth quarter fiscal 2026 earnings call.

Rhea-AI Summary

Azenta (Nasdaq: AZTA) expanded its GENEWIZ gene synthesis capabilities through an exclusive licensing agreement with Elegen and the acquisition of SynPlexity.

The Elegen license adds a cell-free DNA synthesis platform designed to improve DNA quality, delivery speed and manufacturing scalability. It includes sequence-verified DNA constructs and templates for downstream experiments, including antibody discovery. Compact production workflows allow regional capacity to be added near customers as needed.

The completed SynPlexity acquisition adds pooled gene assembly technology that provides thousands of full-length gene variants in a single library, supporting the testing of large numbers of candidates, including AI-generated designs. Azenta expects the investments to expand GENEWIZ's customer offerings and accelerate its growth.

Positive

• Minor pointExclusive Elegen license adds a cell-free DNA synthesis platform to GENEWIZ's portfolio.
• Minor pointSynPlexity acquisition adds pooled gene assembly technology for high-throughput gene libraries.

Negative

• None.

Key Figures

Gene variants per library: Thousands of full-length gene variants

Gene variants per library

Thousands of full-length gene variants

SynPlexity pooled gene assembly

Key Terms

cell-free DNA, high-throughput gene libraries, pooled gene assembly, synthetic biology

4 terms

cell-free DNA technical

"cell-free DNA synthesis platform designed to improve DNA quality"

Fragments of DNA that float freely in the bloodstream after being released by dying or damaged cells, like puzzle pieces carried downstream that hint at what’s happening upstream. Investors care because measuring these fragments enables non‑invasive tests — for example to detect cancer, monitor treatment response, check pregnancy health, or spot organ rejection — so advances, approvals, or reimbursement changes can quickly affect companies that develop the tests and related technologies.

high-throughput gene libraries technical

"providing high-throughput gene libraries for biological discovery"

Collections of thousands to millions of different DNA sequences or genetic variants created and managed so they can be tested quickly and at scale. Laboratories make high-throughput gene libraries by automated synthesis, mutagenesis or combinatorial assembly to explore many sequence changes at once; the libraries are then screened or sequenced with automated, parallel assays to identify variants with desired properties. Because they contain vast numbers of candidates, these libraries require downstream screening, data analysis and validation to determine which sequences have useful biological activity.

pooled gene assembly technical

"adding pooled gene assembly technology"

A laboratory technique that builds many different DNA constructs at once by assembling sets of short synthetic DNA pieces (oligonucleotides or fragments) together in a single pooled reaction. It works by mixing a designed pool of DNA fragments and using enzymatic or ligation-based assembly methods so multiple distinct full-length genes or variants are formed simultaneously; the resulting mixture typically requires downstream separation, sequencing, or selection to identify and isolate the correct or desired products. Because many assemblies occur in the same tube, pooled gene assembly enables high-throughput creation of genetic libraries but can yield mixed, incomplete, or erroneous constructs that must be screened or validated.

synthetic biology technical

"a synthetic biology company providing high-throughput gene libraries"

Synthetic biology is the design and construction of new or modified living systems—like reprogramming cells or microbes—to perform useful tasks such as making materials, medicines, or fuels. For investors it signals a platform technology with potential for high growth and disruption, similar to how software transformed industries: early breakthroughs can create new markets, long-term revenue streams, and also carry technical, regulatory, and ethical risks that affect valuation and timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-throughput discovery workflows, and position GENEWIZ for long-term growth

BURLINGTON, Mass., Oct. 30, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced strategic investments to advance the next phase of growth for its GENEWIZ business. Building on its trusted brand, scientific expertise, global commercial engine, and operational infrastructure, Azenta is expanding its capabilities through an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition of SynPlexity Inc., a synthetic biology company providing high-throughput gene libraries for biological discovery.

The license agreement with Elegen brings into the GENEWIZ portfolio an innovative cell-free DNA synthesis platform designed to improve DNA quality, delivery speed, and manufacturing scalability. Its capabilities include sequence-verified DNA constructs and templates to simplify preparation for downstream experiments, including antibody discovery. The compact production workflows also enable regional capacity to be added close to customers to respond to demand as needed.

Azenta has also acquired SynPlexity, adding pooled gene assembly technology that provides thousands of full-length gene variants in a single library. These capabilities address the increasing scale of biological design by enabling researchers to efficiently build and test large numbers of candidates, including AI-generated designs.

"These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth," said Trey Martin, President, Multiomics at Azenta. "By combining these advanced technologies with our global infrastructure and existing gene-to-antibody portfolio, we are building a differentiated platform poised to accelerate the next era of biologics discovery and development."

Since its founding in New Jersey in 1999, GENEWIZ has built a global sequencing and gene synthesis business grounded in scientific expertise, customer focus, and operational excellence. These investments complement and extend that foundation into higher-growth applications across synthetic biology, protein engineering, and AI-enabled drug discovery.

Additional details will be provided during Azenta's fourth quarter fiscal 2026 earnings call.

About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com

About Elegen 
Elegen uses proprietary cell-free technologies to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries.

About SynPlexity 
SynPlexity is a DNA assembly technology company providing products and services centered on large, multiplexed libraries for functional screening, drug discovery, therapeutics, and other applications.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Azenta's plans to develop, integrate, manufacture and commercialize products using the licensed and acquired technologies and the anticipated benefits of the transactions, including expected improvements in gene synthesis capabilities, expansion of the GENEWIZ offerings and markets, customer adoption and demand, and financial, operational and strategic benefits. Actual results could differ materially from those expressed or implied due to risks and uncertainties, including Azenta's ability to transfer, validate, integrate and scale the technologies, achieve expected technical and commercial performance, protect relevant intellectual property and realize the anticipated benefits, as well as the risks described under "Risk Factors" in Azenta's Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as updated or supplemented by subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and Azenta undertakes no obligation to update them except as required by law.

INVESTOR CONTACT for Azenta Life Sciences:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Maria Isabel Cuartas
Manager, Investor Relations
ir@azenta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-announces-strategic-investments-to-advance-the-next-generation-of-genewiz-gene-synthesis-capabilities-302924585.html

SOURCE Azenta

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Azenta's Elegen licensing agreement add to GENEWIZ?

The exclusive Elegen license adds a cell-free DNA synthesis platform to GENEWIZ. The platform is designed to improve DNA quality, delivery speed and manufacturing scalability, with sequence-verified constructs and templates for downstream experiments.

What did Azenta acquire through the SynPlexity deal?

Azenta acquired SynPlexity, adding pooled gene assembly technology that provides thousands of full-length gene variants in a single library. The technology supports building and testing large numbers of candidates, including AI-generated designs.

When will Azenta provide more details about its GENEWIZ investments?

Additional details will be provided during Azenta's fourth quarter fiscal 2026 earnings call.